Parallel Advisors’s Summit Therapeutics SMMT Stock Holding History

Parallel Advisors’s Portfolio SMMT Stock Details SMMT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.88K	Sell	129 -2,010	-94%	-$35.6K	﹤0.01%	3533
2026 Q1	$40.6K	Buy	2,139 +2,089	+4,178%	+$33.8K	﹤0.01%	2114
2025 Q4	$875	Sell	50 -1,814	-97%	-$34.1K	﹤0.01%	3318
2025 Q3	$38.5K	Sell	1,864 -178	-9%	-$4.32K	﹤0.01%	1919
2025 Q2	$43.5K	Buy	2,042 +2,023	+10,647%	+$46.1K	﹤0.01%	1801
2025 Q1	$367	Buy	+19	New	+$381	﹤0.01%	3287
2023 Q2	–	Sell	-216	Closed	-$378	–	3508
2023 Q1	$378	Buy	+216	New	+$589	﹤0.01%	3186
2022 Q2	–	Sell	-46	Closed	–	–	3331
2022 Q1	$0	Hold	46	–	–	﹤0.01%	3253
2021 Q4	$0	Sell	46 -376	-89%	-$1.81K	﹤0.01%	3277
2021 Q3	$2K	Sell	422 -36	-8%	-$258	﹤0.01%	2732
2021 Q2	$3K	Buy	458 +61	+15%	+$400	﹤0.01%	2493
2021 Q1	$2K	Buy	397 +150	+61%	+$968	﹤0.01%	2516
2020 Q4	$1K	Buy	+247	New	+$1.05K	﹤0.01%	2483

Other funds holding SMMT

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

Parallel Advisors's SMMT Position: Q2 2026 in Review

Parallel Advisors reduced its Summit Therapeutics (SMMT) stake by 94% in Q2 2026, selling an estimated $35.6K and leaving 129 shares worth $1.88K. The position accounts for ﹤0.01% of the portfolio, ranked #3533.

Parallel Advisors first reported a position in SMMT in Q4 2020 and has held it in 13 quarters since. The position peaked at $43.5K in Q2 2025. 242 funds tracked by Wall St. Rank hold SMMT as of Q2 2026.

Parallel Advisors held 129 shares of Summit Therapeutics worth $1.88K as of Q2 2026.
Parallel Advisors sold 2,010 Summit Therapeutics shares in Q2 2026, an estimated $35.6K.
Summit Therapeutics made up ﹤0.01% of Parallel Advisors's portfolio in Q2 2026, its #3533 holding.
Parallel Advisors first reported a position in Summit Therapeutics in Q4 2020 and has held it in 13 quarters since.
Parallel Advisors's Summit Therapeutics position peaked at $43.5K in Q2 2025.
242 funds tracked by Wall St. Rank held Summit Therapeutics as of Q2 2026.

Based on Parallel Advisors's 13F filing for Q2 2026, filed 5 Aug 2026.